Share This Article:

Self-Reported Adherence after Overnight Switching from Immediate- to Extended-Release Pramipexole in Parkinson’s Disease

Full-Text HTML XML Download Download as PDF (Size:1210KB) PP. 13-19
DOI: 10.4236/apd.2015.41003    3,375 Downloads   3,792 Views  

ABSTRACT

Background: Drug adherence decreased in patients with Parkinson’ s disease (PD) because of taking many different types of drugs. We evaluated drug adherence after switching from immediate-release (IR) to once-daily extended-release (ER) pramipexole (PPX) in PD. Methods: This study included 35 PD patients (20 men, 15 women); 10 were taking oral PPX alone, and 25 were also using another anti-PD drug. PPX-IR was switched overnight to PPX-ER without gradual tapering. One month after switching, improvement in timing adherence and reduction in medication burden were evaluated by a questionnaire using a visual analog scale (VAS) (0: No change; 10: Better). Motor function was assessed using part III of the Unified Parkinson’s Disease Rating Scale (UPDRS). Results: The VAS score for improvement in timing adherence was 8.1 ± 0.5 (mean ± standard error), and that for reduction in medication burden was 7.3 ± 0.6. There was a significant negative correlation (ρ = -0.43, p = 0.01) between the VAS score and number of types of medications. The UPDRS part III score improved significantly after switching (p < 0.01). Only one patient discontinued PPX-ER after switching. Conclusion: Switching from PPX-IR to once-daily PPX-ER is safe and improves motor function in patients by improving timing adherence and reducing medication burden.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Iijima, M. , Osawa, M. , Maruyama, K. , Uchiyama, S. and Kitagawa, K. (2015) Self-Reported Adherence after Overnight Switching from Immediate- to Extended-Release Pramipexole in Parkinson’s Disease. Advances in Parkinson's Disease, 4, 13-19. doi: 10.4236/apd.2015.41003.

References

[1] Leopold, N.A., Polansky, M. and Hurka, M.R. (2004) Drug Adherence in Parkinson’s Disease. Movement Disorders, 19, 513-517. http://dx.doi.org/10.1002/mds.20041
[2] Grosset, D.G., Antonini, A., Canesi, M., Pezzoli, G., Lees, A., Shaw, K., Esther Cubo, E., Martinez-Martin, P., Rascol, O., Negre-Pages, L., Senard, A., Schwarz, J., Strecker, K., Reichmann, H., Storch, A., L?hle, M., Stocchi, F. and Grosset, K. (2009) Adherence to Antiparkinson Medication in a Multicenter European Study. Movement Disorders, 24, 826-832. http://dx.doi.org/10.1002/mds.22112
[3] Kulkarni, A.S., Balkrishnan, R., Anderson, R.T., Edin, H.M., Kirsch, J. and Stacy, M.A. (2009) Medication Adherence and Associated Outcomes in Medicare Health Maintenance Organization-Enrolled Older Adults with Parkinson’s Disease. Movement Disorders, 23, 359-365. http://dx.doi.org/10.1002/mds.21831
[4] Valldeoriola, F., Coronell, C., Pont, C., Cámara, C., Gaig , C. and Compta, Y., on Behalf of the Members of the ADHESON Study Group (2011) Socio-Demographic and Clinical Factors Influencing the Adherence to Treatment in Parkinson’s Disease: The ADHESON Study. European Journal of Neurology, 13, 980-987. http://dx.doi.org/10.1111/j.1468-1331.2010.03320.x
[5] Daley, D.J., Myint, P.K., Gray, R.J. and Deane, K.H. (2012) Systematic Review on Factors Associated with Medication Non-Adherence in Parkinson’s Disease. Parkinsonism & Related Disorders 18, 1053-1061. http://dx.doi.org/10.1016/j.parkreldis.2012.09.004
[6] Schapira, A.H.V., Barone, P., Hauser, R.A., et al. (2013) Patient-Reported Convenience of Once-Daily versus Three- Times-Daily Dosing during Long-Term Studies of Pramipexole in Early and Advanced Parkinson’ s Disease. European Journal of Neurology, 20, 50-56. http://dx.doi.org/10.1111/j.1468-1331.2012.03712.x
[7] Takanashi, M., Shimo, Y., Hatano, T., Oyama, G. and Hattori, N. (2013) Efficacy and Safety of a Once-Daily Extended-Release Formulation of Pramipexole Switched from an Immediate-Release Formulation in Patients with Advanced Parkinson’s Disease: Results from an Open-Label Study. Drug Research, 63, 639-643. http://dx.doi.org/10.1055/s-0033-1351257
[8] Grosset, K.A. and Grosset, D.G. (2007) Effect of Educational Intervention on Medication Timing in Parkinson’s Disease: A Randomized Controlled Trial. BMC Neurology, 7, 20. http://dx.doi.org/10.1186/1471-2377-7-20
[9] Santos-García, D., Prieto-Formoso, M. and Fuente-Fernández, R. (2012) Levodopa Dosage Determines Adherence to Long-Acting Dopamine Agonists in Parkinson’s Disease. Journal of the Neurological Sciences, 318, 90-93. http://dx.doi.org/10.1016/j.jns.2012.03.018
[10] Grosset, K.A., Bone, I., Reid, J.L. and Grosset, D.G. (2006) Measuring Therapy Adherence in Parkinson’s Disease: A Comparison of Methods. Journal of Neurology, Neurosurgery & Psychiatry, 77, 249-251. http://dx.doi.org/10.1136/jnnp.2005.064709
[11] Elm, J.J., Kamp, C., Tilley, B.C., Guimaraes, P., Fraser, D., Deppen, P., Brocht, A., Weaver, C., Bennett, S., for NINDS NET-PD Investigators and Coordinators (2007) Self-Reported Adherence versus Pill Count in Parkinson’s Disease: The NET-PD Experience. Movement Disorders, 22, 822-827. http://dx.doi.org/10.1002/mds.21409
[12] Tarrants, M.L., Denarié, M.F., Castelli-Haley, J., Millard, J. and Zhang, D. (2010) Drug Therapies for Parkinson’s Disease: A Database Analysis of Patient Compliance and Persistence. The American Journal of Geriatric Pharmacotherapy, 8, 374-383. http://dx.doi.org/10.1016/j.amjopharm.2010.08.001
[13] Rascol, O., Barone, P., Hauser, R.A., Mizuno, Y., Poewe, W., Schapira, A.H.V., Salin, L., Sohr, M. and Debieuvre, C. (2010) Efficacy, Safety, and Tolerability of Overnight Switching from Immediate- to Once Daily Extended-Release Pramipexole in Early Parkinson’s Disease. Movement Disorders, 25, 2326-2332. http://dx.doi.org/10.1002/mds.23262
[14] Mizuo, Y., Yamamoto, M., Kuno, S., Hasegawa, K., Hattori, N., Kagimura, T., Sarashina, A., Rascol, O., Schapira, A.H.V., Barone, P., Hauser, R., Poewe, W., The Pramipexole ER Study Group (2012) Efficacy and Safety of Extended- versus Immediate- Release Pramipexole in Japanese Patients with Advanced and L-dopa-Undertreated Parkinson Disease: A Double-Blind, Randomized Trial. Clinical Neuropharmacology, 35, 174-181. http://dx.doi.org/10.1097/WNF.0b013e31825f77b9
[15] Schapira, A.H., Barone, P., Hauser, R.A., Mizuno, Y., Rascol, O., Busse, M., Debieuvre, C., Fraessdorf, N. and Poewe, W. (2013) Success Rate, Efficacy, and Safety/Tolerability of Overnight Switching from Immediate- to Extended-Re- lease Pramipexole in Advanced Parkinson’s Disease. European Journal of Neurology, 20, 180-187. http://dx.doi.org/10.1111/j.1468-1331.2012.03822.x
[16] Bainbridge, J.L. and Ruscin, J. (2009) Challenges of Treatment Adherence in Older Patients with Parkinson’s Disease. Drugs & Aging, 26,145-155. http://dx.doi.org/10.2165/0002512-200926020-00006

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.